Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab

Immunotherapy is an established treatment modality in oncology. However, in addition to primary or acquired therapy resistance with immune checkpoint blockade (ICB), hyperprogressive disease (HPD) or hyperprogression (HP) with acceleration of tumor growth occurs in a subset of patients receiving ICB...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahin, Ilyas, George, Andrew, Zhang, Shengliang, Huntington, Kelsey E., Ordulu, Zehra, Zhou, Lanlan, El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522841/
https://www.ncbi.nlm.nih.gov/pubmed/34676046
http://dx.doi.org/10.18632/oncotarget.28086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522841/
https://www.ncbi.nlm.nih.gov/pubmed/34676046
http://dx.doi.org/10.18632/oncotarget.28086

Ejemplares similares